Pfizer Inc. (NYSE:PFE) Develops Branded Prescription Drugs For Cardiovascular And Metabolic Diseases And Other Conditions. Belonging to the Medical sector which surged 1.65% and closed its last trading session at $33.87.
The company reported its last EPS on 6/30/2016 and is expected to report its next EPS on 11/1/2016. Currently, the stock has a 1 Year Price Target of $39.4.
The consensus recommendation, according to Zacks Investment research, is 1.92. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 1.92 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.86 and 1.8 respectively.
Pfizer Inc. on 6/30/2016 reported its EPS as $0.64 with the analysts projecting the EPS of the stock as $0.62. The company beat the analyst EPS Estimate with the difference of $0.02. This shows a surprise factor of 3.2%.
Many analysts have provided their estimated foresights on Pfizer Inc. Earnings, with 17 analysts believing the company would generate an Average Estimate of $0.61. Whereas they predicted High and Low Earnings Estimate as $0.65 and $0.57 respectively. While in the same Quarter Previous year, the Actual EPS was $0.6.
Analysts are also projecting an Average Revenue Estimate for Pfizer Inc. as $13.08 Billion in the Current Quarter. This estimate is provided by 14 analysts. The High Revenue estimate is predicted as 13.44 Billion, while the Low Revenue Estimate prediction stands at 12.7 Billion. The company’s last year sales total was 12.09 Billion.
For the Current Quarter, the growth estimate for Pfizer Inc. is 1.7%, while for the Next Quarter the stock growth estimate is 1.9%. In the past 5 years, the stock showed growth of 1.05% per annum. While for the next 5 years, the growth estimate is 6.52%.
The Company got Initiated by Berenberg on 12-May-16 to Hold.
Insider Trades for Pfizer Inc. show that the latest trade was made on 2 Aug 2016 where Read (Ian C), the Chief Executive Officer completed a transaction type “Sell” in which 954993 shares were traded at a price of $35.29.
3 Insider Sales transactions were made totaling 93574 shares traded.
20 analysts projected Price Targets for Pfizer Inc. The analysts believe that the company stock price could grow as high as $54. The Low Price target projection by analysts is $33 and the Mean Price Target is $39.4.
Pfizer Inc. (NYSE:PFE) has the market capitalization of $205.52 Billion. The company rocked its 52-Week High of $37.39 on Aug 1, 2016 and touched its 52-Week Low of $28.25 on Feb 8, 2016. The stock has Return on Assets (ROA) of 4.2 percent. Return on Equity (ROE) stands at 10.9% and Return on Investment (ROI) of 7.3 percent.
The stock is currently showing YTD performance of 7.82 Percent. The company has Beta Value of 0.87 and ATR value of 0.49. The Weekly and Monthly Volatility stands at 1.61% and 1.34%.
Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Pfizer’s Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. is headquartered in New York.